HEALTHCARE
Teva on course for 2027 targets
The Israeli pharmaceutical company's 3,000 layoffs will help the company achieve its targets for growth and higher profitability.
Teva receives FDA approval for biosimilar
The FDA has ruled that SELARSDI, which Teva has launched with Alvotech, is interchangeable with Stelara for treating adult and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohn's disease, and ulcerative colitis.
Making a better world for the disabled
Personal experience motivated Roy Goldenberg to become Israel director of TOM Tikkun Olam Makers. "TOM will be one of the biggest organizations to come out of Israel," he says.
Analysts remain positive on Teva
The company's 2025 guidance sent its share price tumbling, but analysts stress its investment in its innovative pipeline and debt reduction.